33c share price target by July 2021, page-274

The most hilarious thing is that Botanix was valued at this current market cap going into ph2 acne results only.

Now we are valued this way with SB near approved, acne given the green light into phase 3, rosacea kicking goals and BTX1801 that shows synthetic cannabidiol rapidly kills MRSA within 10 minutes of exposure by a novel mechanism of action and without allowing resistance to develop.

The market is completely dismissing the BTX1801, BTX 1503 and BTX1702 pipelines which if stood alone in other companies would be at the current market cap that we sit.

The opportunity this company presents over the next six months is mind blowing and I expect a re-rate quickly to 500 mill+ market cap and towards 1 billion on FDA approval.

Hold on!